University of Pittsburgh Cancer Institute (UPCI)

Clinical Trials

Clinical TrialsClinical investigators in the CTP design and perform Phase I, Phase I/II, and Phase II studies of small molecule anticancer agents, either alone or in combination with other drugs.

Selected Publications

  • Irinotecan and weekly cetuximab (I+C) is a standard second-line regimen for metastatic colorectal cancer (mCRC). Patients with mCRC refractory to first-line fluoropyrimidine/oxaliplatin regimens and not previously treated with I+C were treated every 2 weeks with I+C. No efficacy of this combination was demonstrated at the dose and schedule tested (Carneiro BA et. al. Clin Colorectal Cancer. 11:53-9, 2012).
  • The addition of bevacizumab to paclitaxel improved progression-free survival of patients with metastatic breast cancer. In a phase II clinical trial, CTP investigators examined the efficacy and safety of adding gemcitabine to paclitaxel/bevacizumab. Although this triple drug regimen generally was well tolerated, it did not improve the overall response rate (Brufsky A et. al. Clin Breast Cancer 11:211-20, 2011).
  • MTTDP participated in a phase III clinical study that compared the efficacy and safety of bevacizumab combined with standard chemotherapy regimens versus chemotherapy alone as second-line treatment of patients with human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer. The combination of bevacizumab with commonly used chemotherapies improved progression-free survival in the second-line treatment of patients with HER2-negative metastatic breast cancer, with a safety profile comparable with that in prior phase III studies (Brufsky AM et. al. J Clin Oncol 29:4286-93, 2011).

Members

Appleman, Leonard, MD, PhD
Medicine
Mountz, James, MD, PhD
Radiology
Bahary, Nathan, MD, PhD
Medicine
Ragni, Margaret, MD, MPH
Medicine
Jakacki, Regina, MD
Pediatrics (CHP)
Redner, Robert, MD
Medicine
Maranchie, Jodi, MD, FACS
Urology
Stoller, Ronald, MD
Medicine